Clinical Trial: Phase II Pegylated Interferon

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional



Official Title: A Phase II Study Of Pegylated Interferon ALFA-2b in Children With Recurrent or Refractory and Radiographically or Clinically Progressive Juvenile Pilocytic Astrocytomas an

Brief Summary:

This is a phase II study of the drug, pegylated interferon alfa-2b (PEG-IntronTM), used to treat brain tumors in a pediatric population. Researchers want to see if treatment with PEG-IntronTM will stop tumor growth for patients with juvenile pilocytic astrocytomas or optic pathway gliomas.

The purposes of this study are:

  • To learn more about the response to pegylated interferon
  • To learn more about the side effects of pegylated interferon
  • To learn more about MRI images in patients with Juvenile Pilocytic Astrocytomas or Optic Pathway Gliomas.
  • To learn more about quality of life in patients treated with pegylated interferon